PFE241129P31500
- 5.63
- -0.26-4.41%
Pfizer Newsroom
Morgan Stanley Sticks to Their Hold Rating for Pfizer (PFE)
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating
Wolfe Research Initiates Pfizer at Underperform With $25 Price Target
Pfizer Analyst Ratings
Wolfe Research Downgrades Pfizer(PFE.US) to Sell Rating, Announces Target Price $25
Pfizer Initiated With an Underperform at Wolfe Research
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
UBS Remains a Hold on Pfizer (PFE)
CFRA Upgrades Pfizer(PFE.US) to Buy Rating, Cuts Target Price to $30
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
Jefferies Remains a Buy on Pfizer (PFE)
Daiwa Securities Adjusts Pfizer's Price Target to $28 From $34, Keeps Outperform Rating
Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Evercore Maintains Pfizer(PFE.US) With Buy Rating
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Barclays Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
UBS Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $31
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $31 to $33
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $30 to $36